Free tools like Ollama and LM Studio can run local AI models on your laptop, offline, and without a subscription. Here's how ...

An open access tutorial in Advances in Simulation provides a five-step, code-inclusive introduction to cardiopulmonary ...

A major phase 3 clinical trial was widely expected to confirm the lipoprotein(a) [Lp(a)] hypothesis — that lowering it yields cardiovascular benefit. Harpreet Bhatia, MD When the disappointing results ...

Most confusion comes from mixing 2 layers. A container defines how tensors are stored on disk. A quantization method defines how weights are squeezed into fewer bits. Unquantized models usually ship ...

The Family Heart Foundation has published a new study in JACC: Advances demonstrating how its FIND Lp (a) Machine Learning Model can identify people with atherosclerotic cardiovascular disease (ASCVD) ...

FERNANDINA BEACH, Fla.--(BUSINESS WIRE)--The Family Heart Foundation, a leading research, education and advocacy organization, today announced the publication of a new peer-reviewed study in JACC: ...

The much-anticipated Lp(a)HORIZON trial testing whether the novel drug pelacarsen can improve cardiovascular outcomes by decreasing lipoprotein(a) levels has failed to meet its primary endpoint.

Novartis’ pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.

Please provide your email address to receive an email when new articles are posted on . Pelacarsen did not reduce cardiovascular events in patients with elevated lipoprotein(a) compared with placebo.

The result calls into question other late-stage trials testing Lp(a)-lowering drugs from the likes of Amgen and Eli Lilly. (iStock / Getty Images Plus) Novartis’ Ionis-partnered drug designed to lower ...